Share Price and Basic Stock Data
Last Updated: November 28, 2025, 11:41 am
| PEG Ratio | 2.79 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lactose (India) Ltd operates in the pharmaceuticals sector, focusing on the production and sale of lactose products. The company reported a revenue from operations of ₹137 Cr for the trailing twelve months (TTM), marking a significant increase from ₹116 Cr in FY 2025 and ₹114 Cr in FY 2024. The quarterly sales figures indicate a robust growth trajectory, with sales rising from ₹9.62 Cr in June 2022 to ₹27.77 Cr in March 2025. The company recorded a notable peak of ₹39.58 Cr in June 2025, reflecting strong demand for its products. This upward trend in sales is indicative of effective market penetration and product acceptance. Despite some fluctuations, such as a decline to ₹24.43 Cr in September 2023, Lactose has demonstrated resilience in its revenue generation, suggesting a solid operational foundation. The overall growth in sales aligns with the increasing demand in the pharmaceutical sector, bolstered by a growing healthcare market in India.
Profitability and Efficiency Metrics
Lactose (India) Ltd’s profitability metrics reveal a mixed performance. The operating profit margin (OPM) stood at 11.29% as of the latest reporting period, down from a peak of 27% in FY 2022. The company’s net profit rose to ₹5 Cr in FY 2025, reflecting an increase from ₹1 Cr in FY 2023. However, the OPM’s decline over recent quarters indicates rising operational costs, which require attention. The interest coverage ratio (ICR) of 3.02x signifies that the company is comfortably covering its interest obligations, a positive indicator for financial health. Return on equity (ROE) stood at 9.69%, suggesting moderate returns for shareholders relative to their equity investment. The cash conversion cycle, reported at 165 days, indicates a longer duration to convert investments in inventory and receivables into cash, which may affect liquidity positions. Overall, while profitability metrics show improvement, efficiency in managing costs and cash flow needs to be prioritized.
Balance Sheet Strength and Financial Ratios
Lactose (India) Ltd’s balance sheet reflects a growing financial position with total assets reported at ₹133 Cr as of FY 2025, up from ₹101 Cr in FY 2024. The company’s total borrowings stood at ₹57 Cr, which indicates a manageable debt level, giving a debt-to-equity ratio of 0.95x. This ratio is within a typical range for the pharmaceuticals sector, suggesting a balance between leveraging for growth and maintaining financial stability. Reserves have increased to ₹46 Cr, providing a cushion for future investments and operations. The price-to-book value (P/BV) ratio of 1.90x suggests that the stock is trading at a reasonable valuation compared to its book value, which stood at ₹46.66 per share. The current ratio of 1.28 indicates sufficient short-term liquidity, while the inventory turnover ratio of 2.93x signifies efficient inventory management. However, the long-term debt-to-equity ratio of 0.44x reflects a reliance on equity financing, which may limit growth if not balanced with strategic debt utilization.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lactose (India) Ltd indicates a stable ownership structure, with promoters holding 53.65% of the shares as of March 2025. This level of promoter holding is generally viewed positively, as it reflects confidence from the management in the company’s future. Domestic institutional investors (DIIs) hold a minimal stake of 0.62%, while the public holds 45.73%. The total number of shareholders has increased to 16,810, suggesting growing interest in the company. This rise in shareholder base can be interpreted as a sign of increasing investor confidence, potentially driven by the company’s performance improvements and growth prospects. However, the absence of foreign institutional investment (FIIs) may indicate a lack of international interest, which could limit the stock’s upside potential. Overall, the stable promoter stake combined with a growing public interest presents a balanced outlook for investor confidence in Lactose.
Outlook, Risks, and Final Insight
The outlook for Lactose (India) Ltd appears cautiously optimistic, driven by its revenue growth and improving profitability metrics. However, risks remain, particularly concerning rising operational costs, as evidenced by the declining OPM and increased cash conversion cycle. The pharmaceutical sector’s inherent challenges, including regulatory scrutiny and competition, could impact future performance. Additionally, the company’s reliance on domestic markets, with no significant foreign institutional backing, may limit its growth potential. Strengths include a solid balance sheet with manageable debt levels and increasing reserves, which provide a buffer for future investments. If Lactose can enhance operational efficiency and maintain its growth trajectory, it stands to benefit from the expanding pharmaceutical market in India. Conversely, failure to address rising costs and optimize cash flows could hinder its performance. The company’s ability to navigate these challenges will be critical in determining future success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Lactose (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 164 Cr. | 130 | 247/84.3 | 36.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,467 Cr. | 410 | 479/192 | 92.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.0 Cr. | 28.0 | 29.3/17.0 | 97.7 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,336.40 Cr | 1,175.88 | 52.22 | 202.44 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.62 | 13.17 | 17.02 | 25.99 | 27.47 | 24.43 | 32.60 | 29.40 | 29.46 | 30.45 | 28.72 | 27.77 | 39.58 |
| Expenses | 7.34 | 10.82 | 14.29 | 21.99 | 23.70 | 21.04 | 26.88 | 23.28 | 23.88 | 25.44 | 25.75 | 24.36 | 35.11 |
| Operating Profit | 2.28 | 2.35 | 2.73 | 4.00 | 3.77 | 3.39 | 5.72 | 6.12 | 5.58 | 5.01 | 2.97 | 3.41 | 4.47 |
| OPM % | 23.70% | 17.84% | 16.04% | 15.39% | 13.72% | 13.88% | 17.55% | 20.82% | 18.94% | 16.45% | 10.34% | 12.28% | 11.29% |
| Other Income | 0.23 | 0.20 | 0.16 | 0.14 | 0.28 | 0.26 | 0.28 | 0.31 | 0.22 | 0.30 | 0.56 | 0.37 | 0.41 |
| Interest | 1.24 | 1.31 | 1.55 | 1.84 | 1.55 | 1.31 | 1.21 | 1.17 | 1.26 | 1.37 | 1.64 | 1.84 | 1.22 |
| Depreciation | 1.16 | 1.17 | 1.17 | 1.19 | 1.19 | 1.20 | 1.20 | 1.63 | 1.31 | 1.33 | 1.35 | 1.39 | 1.37 |
| Profit before tax | 0.11 | 0.07 | 0.17 | 1.11 | 1.31 | 1.14 | 3.59 | 3.63 | 3.23 | 2.61 | 0.54 | 0.55 | 2.29 |
| Tax % | 18.18% | -14.29% | 11.76% | 20.72% | 26.72% | 28.95% | 27.02% | 33.88% | 29.72% | 22.22% | 59.26% | -18.18% | 34.50% |
| Net Profit | 0.09 | 0.09 | 0.14 | 0.89 | 0.96 | 0.81 | 2.63 | 2.40 | 2.27 | 2.03 | 0.22 | 0.64 | 1.50 |
| EPS in Rs | 0.07 | 0.07 | 0.11 | 0.71 | 0.76 | 0.64 | 2.09 | 1.91 | 1.80 | 1.61 | 0.17 | 0.51 | 1.19 |
Last Updated: August 19, 2025, 12:44 pm
Below is a detailed analysis of the quarterly data for Lactose (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 39.58 Cr.. The value appears strong and on an upward trend. It has increased from 27.77 Cr. (Mar 2025) to 39.58 Cr., marking an increase of 11.81 Cr..
- For Expenses, as of Jun 2025, the value is 35.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.36 Cr. (Mar 2025) to 35.11 Cr., marking an increase of 10.75 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.47 Cr.. The value appears strong and on an upward trend. It has increased from 3.41 Cr. (Mar 2025) to 4.47 Cr., marking an increase of 1.06 Cr..
- For OPM %, as of Jun 2025, the value is 11.29%. The value appears to be declining and may need further review. It has decreased from 12.28% (Mar 2025) to 11.29%, marking a decrease of 0.99%.
- For Other Income, as of Jun 2025, the value is 0.41 Cr.. The value appears strong and on an upward trend. It has increased from 0.37 Cr. (Mar 2025) to 0.41 Cr., marking an increase of 0.04 Cr..
- For Interest, as of Jun 2025, the value is 1.22 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.84 Cr. (Mar 2025) to 1.22 Cr., marking a decrease of 0.62 Cr..
- For Depreciation, as of Jun 2025, the value is 1.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.39 Cr. (Mar 2025) to 1.37 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 2.29 Cr.. The value appears strong and on an upward trend. It has increased from 0.55 Cr. (Mar 2025) to 2.29 Cr., marking an increase of 1.74 Cr..
- For Tax %, as of Jun 2025, the value is 34.50%. The value appears to be increasing, which may not be favorable. It has increased from -18.18% (Mar 2025) to 34.50%, marking an increase of 52.68%.
- For Net Profit, as of Jun 2025, the value is 1.50 Cr.. The value appears strong and on an upward trend. It has increased from 0.64 Cr. (Mar 2025) to 1.50 Cr., marking an increase of 0.86 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.19. The value appears strong and on an upward trend. It has increased from 0.51 (Mar 2025) to 1.19, marking an increase of 0.68.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:00 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 24 | 34 | 36 | 31 | 41 | 40 | 35 | 46 | 66 | 114 | 116 | 137 |
| Expenses | 21 | 19 | 24 | 24 | 25 | 31 | 31 | 29 | 34 | 54 | 95 | 99 | 121 |
| Operating Profit | 1 | 5 | 10 | 11 | 6 | 10 | 9 | 6 | 12 | 11 | 19 | 17 | 16 |
| OPM % | 5% | 22% | 30% | 32% | 18% | 24% | 23% | 18% | 27% | 17% | 17% | 15% | 12% |
| Other Income | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Interest | 1 | 3 | 4 | 4 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 6 | 6 |
| Depreciation | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 |
| Profit before tax | 0 | 1 | 4 | 4 | -3 | 1 | 0 | -3 | 3 | 1 | 10 | 7 | 7 |
| Tax % | 60% | 42% | 28% | 36% | -52% | 33% | 30% | -24% | 23% | 18% | 30% | 25% | |
| Net Profit | 0 | 0 | 3 | 3 | -1 | 1 | 0 | -2 | 2 | 1 | 7 | 5 | 5 |
| EPS in Rs | 0.04 | 0.59 | 3.17 | 2.87 | -1.32 | 0.71 | 0.07 | -2.17 | 1.95 | 0.96 | 5.39 | 4.10 | 3.59 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -133.33% | 200.00% | -100.00% | 200.00% | -50.00% | 600.00% | -28.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | 333.33% | -300.00% | 300.00% | -250.00% | 650.00% | -628.57% |
Lactose (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 24% |
| 3 Years: | 36% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 136% |
| 3 Years: | 29% |
| TTM: | -46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 39% |
| 3 Years: | 20% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:55 pm
Balance Sheet
Last Updated: August 11, 2025, 4:19 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 10 | 10 | 10 | 10 | 11 | 13 | 13 | 13 | 13 |
| Reserves | 7 | 7 | 12 | 17 | 22 | 24 | 24 | 24 | 27 | 28 | 35 | 46 |
| Borrowings | 23 | 39 | 37 | 34 | 38 | 36 | 39 | 46 | 41 | 38 | 39 | 57 |
| Other Liabilities | 22 | 25 | 26 | 24 | 13 | 11 | 10 | 7 | 10 | 22 | 14 | 18 |
| Total Liabilities | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 |
| Fixed Assets | 28 | 62 | 61 | 64 | 63 | 60 | 62 | 59 | 59 | 56 | 55 | 52 |
| CWIP | 15 | 1 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 10 |
| Investments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Other Assets | 16 | 15 | 21 | 20 | 19 | 20 | 22 | 25 | 30 | 45 | 46 | 71 |
| Total Assets | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 |
Below is a detailed analysis of the balance sheet data for Lactose (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
- For Reserves, as of Mar 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2024) to 46.00 Cr., marking an increase of 11.00 Cr..
- For Borrowings, as of Mar 2025, the value is 57.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 39.00 Cr. (Mar 2024) to 57.00 Cr., marking an increase of 18.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 18.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Mar 2024) to 18.00 Cr., marking an increase of 4.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 133.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Mar 2024) to 133.00 Cr., marking an increase of 32.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 55.00 Cr. (Mar 2024) to 52.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Mar 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 10.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 71.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2024) to 71.00 Cr., marking an increase of 25.00 Cr..
- For Total Assets, as of Mar 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 101.00 Cr. (Mar 2024) to 133.00 Cr., marking an increase of 32.00 Cr..
However, the Borrowings (57.00 Cr.) are higher than the Reserves (46.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -22.00 | -34.00 | -27.00 | -23.00 | -32.00 | -26.00 | -30.00 | -40.00 | -29.00 | -27.00 | -20.00 | -40.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 125 | 83 | 96 | 91 | 63 | 62 | 64 | 67 | 90 | 69 | 49 | 68 |
| Inventory Days | 69 | 129 | 344 | 440 | 456 | 384 | 471 | 587 | 343 | 344 | 119 | 171 |
| Days Payable | 308 | 273 | 340 | 559 | 330 | 242 | 202 | 153 | 195 | 275 | 59 | 74 |
| Cash Conversion Cycle | -114 | -61 | 100 | -27 | 188 | 204 | 333 | 501 | 238 | 138 | 109 | 165 |
| Working Capital Days | -59 | -118 | -100 | -107 | 18 | 42 | 59 | 56 | 46 | 56 | 26 | 24 |
| ROCE % | -3% | 8% | 13% | 15% | 4% | 9% | 8% | 3% | 10% | 9% | 18% | 13% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.10 | 5.39 | 0.96 | 2.10 | -2.40 |
| Diluted EPS (Rs.) | 4.06 | 5.39 | 0.96 | 2.10 | -2.40 |
| Cash EPS (Rs.) | 8.38 | 9.54 | 4.68 | 5.57 | 1.64 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 46.66 | 37.41 | 32.22 | 31.20 | 30.68 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 46.66 | 37.41 | 32.22 | 31.20 | 30.68 |
| Revenue From Operations / Share (Rs.) | 92.46 | 90.47 | 52.26 | 36.49 | 30.57 |
| PBDIT / Share (Rs.) | 14.63 | 15.98 | 9.61 | 10.20 | 5.71 |
| PBIT / Share (Rs.) | 10.34 | 11.84 | 5.89 | 6.58 | 1.90 |
| PBT / Share (Rs.) | 5.50 | 7.68 | 1.16 | 2.52 | -2.86 |
| Net Profit / Share (Rs.) | 4.10 | 5.39 | 0.96 | 1.95 | -2.17 |
| PBDIT Margin (%) | 15.81 | 17.66 | 18.38 | 27.95 | 18.69 |
| PBIT Margin (%) | 11.18 | 13.08 | 11.26 | 18.02 | 6.22 |
| PBT Margin (%) | 5.94 | 8.48 | 2.22 | 6.89 | -9.35 |
| Net Profit Margin (%) | 4.43 | 5.96 | 1.83 | 5.33 | -7.08 |
| Return on Networth / Equity (%) | 8.78 | 14.41 | 2.97 | 6.23 | -7.06 |
| Return on Capital Employeed (%) | 14.70 | 19.78 | 9.85 | 10.99 | 2.83 |
| Return On Assets (%) | 3.86 | 6.73 | 1.18 | 2.71 | -2.80 |
| Long Term Debt / Equity (X) | 0.44 | 0.51 | 0.81 | 0.87 | 1.12 |
| Total Debt / Equity (X) | 0.95 | 0.80 | 0.95 | 1.04 | 1.20 |
| Asset Turnover Ratio (%) | 0.99 | 1.12 | 0.68 | 0.51 | 0.40 |
| Current Ratio (X) | 1.28 | 1.40 | 1.41 | 1.53 | 1.69 |
| Quick Ratio (X) | 0.73 | 0.73 | 0.55 | 1.05 | 0.97 |
| Inventory Turnover Ratio (X) | 2.93 | 2.47 | 2.37 | 0.72 | 0.53 |
| Interest Coverage Ratio (X) | 3.02 | 3.84 | 2.03 | 2.51 | 1.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.85 | 2.30 | 1.20 | 1.48 | 0.54 |
| Enterprise Value (Cr.) | 162.92 | 211.83 | 93.28 | 114.35 | 69.83 |
| EV / Net Operating Revenue (X) | 1.40 | 1.86 | 1.42 | 2.49 | 2.00 |
| EV / EBITDA (X) | 8.85 | 10.53 | 7.71 | 8.91 | 10.68 |
| MarketCap / Net Operating Revenue (X) | 0.95 | 1.54 | 0.84 | 1.64 | 0.87 |
| Price / BV (X) | 1.90 | 3.73 | 1.37 | 1.92 | 0.87 |
| Price / Net Operating Revenue (X) | 0.95 | 1.54 | 0.84 | 1.64 | 0.87 |
| EarningsYield | 0.04 | 0.03 | 0.02 | 0.03 | -0.08 |
After reviewing the key financial ratios for Lactose (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 5. It has decreased from 5.39 (Mar 24) to 4.10, marking a decrease of 1.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.06. This value is below the healthy minimum of 5. It has decreased from 5.39 (Mar 24) to 4.06, marking a decrease of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 8.38. This value is within the healthy range. It has decreased from 9.54 (Mar 24) to 8.38, marking a decrease of 1.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.66. It has increased from 37.41 (Mar 24) to 46.66, marking an increase of 9.25.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.66. It has increased from 37.41 (Mar 24) to 46.66, marking an increase of 9.25.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 92.46. It has increased from 90.47 (Mar 24) to 92.46, marking an increase of 1.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 14.63, marking a decrease of 1.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.34. This value is within the healthy range. It has decreased from 11.84 (Mar 24) to 10.34, marking a decrease of 1.50.
- For PBT / Share (Rs.), as of Mar 25, the value is 5.50. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.50, marking a decrease of 2.18.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.10. This value is within the healthy range. It has decreased from 5.39 (Mar 24) to 4.10, marking a decrease of 1.29.
- For PBDIT Margin (%), as of Mar 25, the value is 15.81. This value is within the healthy range. It has decreased from 17.66 (Mar 24) to 15.81, marking a decrease of 1.85.
- For PBIT Margin (%), as of Mar 25, the value is 11.18. This value is within the healthy range. It has decreased from 13.08 (Mar 24) to 11.18, marking a decrease of 1.90.
- For PBT Margin (%), as of Mar 25, the value is 5.94. This value is below the healthy minimum of 10. It has decreased from 8.48 (Mar 24) to 5.94, marking a decrease of 2.54.
- For Net Profit Margin (%), as of Mar 25, the value is 4.43. This value is below the healthy minimum of 5. It has decreased from 5.96 (Mar 24) to 4.43, marking a decrease of 1.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.78. This value is below the healthy minimum of 15. It has decreased from 14.41 (Mar 24) to 8.78, marking a decrease of 5.63.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.70. This value is within the healthy range. It has decreased from 19.78 (Mar 24) to 14.70, marking a decrease of 5.08.
- For Return On Assets (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 5. It has decreased from 6.73 (Mar 24) to 3.86, marking a decrease of 2.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.95. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 0.95, marking an increase of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.99. It has decreased from 1.12 (Mar 24) to 0.99, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 1.5. It has decreased from 1.40 (Mar 24) to 1.28, marking a decrease of 0.12.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.73.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.93. This value is below the healthy minimum of 4. It has increased from 2.47 (Mar 24) to 2.93, marking an increase of 0.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.02. This value is within the healthy range. It has decreased from 3.84 (Mar 24) to 3.02, marking a decrease of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 3. It has decreased from 2.30 (Mar 24) to 1.85, marking a decrease of 0.45.
- For Enterprise Value (Cr.), as of Mar 25, the value is 162.92. It has decreased from 211.83 (Mar 24) to 162.92, marking a decrease of 48.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has decreased from 1.86 (Mar 24) to 1.40, marking a decrease of 0.46.
- For EV / EBITDA (X), as of Mar 25, the value is 8.85. This value is within the healthy range. It has decreased from 10.53 (Mar 24) to 8.85, marking a decrease of 1.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.54 (Mar 24) to 0.95, marking a decrease of 0.59.
- For Price / BV (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has decreased from 3.73 (Mar 24) to 1.90, marking a decrease of 1.83.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.54 (Mar 24) to 0.95, marking a decrease of 0.59.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lactose (India) Ltd:
- Net Profit Margin: 4.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.78% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.2 (Industry average Stock P/E: 52.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.95
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Survey No.5,6,7A, Vadodra District Gujarat 391780 | lil@lactoseindialimited.com http://www.lactoseindialimited.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Atul Maheshwari | Managing Director |
| Mrs. Sangita Maheshwari | WholeTime Director & CFO |
| Mr. Dhaval Jayant Soni | Ind. Non-Executive Director |
| Mr. Nandan Srinath | Ind. Non-Executive Director |
| Mr. Chandra Mohan Bhagavatula | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Lactose (India) Ltd?
Lactose (India) Ltd's intrinsic value (as of 28 November 2025) is 141.97 which is 9.21% higher the current market price of 130.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 164 Cr. market cap, FY2025-2026 high/low of 247/84.3, reserves of ₹46 Cr, and liabilities of 133 Cr.
What is the Market Cap of Lactose (India) Ltd?
The Market Cap of Lactose (India) Ltd is 164 Cr..
What is the current Stock Price of Lactose (India) Ltd as on 28 November 2025?
The current stock price of Lactose (India) Ltd as on 28 November 2025 is 130.
What is the High / Low of Lactose (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lactose (India) Ltd stocks is 247/84.3.
What is the Stock P/E of Lactose (India) Ltd?
The Stock P/E of Lactose (India) Ltd is 36.2.
What is the Book Value of Lactose (India) Ltd?
The Book Value of Lactose (India) Ltd is 49.6.
What is the Dividend Yield of Lactose (India) Ltd?
The Dividend Yield of Lactose (India) Ltd is 0.00 %.
What is the ROCE of Lactose (India) Ltd?
The ROCE of Lactose (India) Ltd is 12.9 %.
What is the ROE of Lactose (India) Ltd?
The ROE of Lactose (India) Ltd is 9.69 %.
What is the Face Value of Lactose (India) Ltd?
The Face Value of Lactose (India) Ltd is 10.0.